Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced it has secured $69 million in a Series B financing and in a separate agreement entered an exclusive licensing deal with Huadong Medicine.
Ashvattha will present two oral presentations at the virtual World Molecular Imaging Congress (WMIC), on October 5-8, 2021.
Ashvattha Chairman, CEO and President Jeffrey Cleland, Ph.D., will be presenting at various virtual and in-person investor conferences in September and October.
Ashvattha announced positive interim results from its ongoing multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hyperinflammation in hospitalized adults with severe COVID-19.
Ashvattha will present at the Sachs 7th Annual Immuno-Oncology Innovation Forum, held virtually on May 18-20
Ashvattha announced the presentation of a virtual poster supporting the development of its proprietary HDT, D-4517, for treatment of AMD at the 2021 ARVO Annual Meeting.
Ashvattha initiates a preclinical proof of concept study for OP-801 imaging of neuroinflammation. This Investigational New Drug (IND)-enabling research will be conducted in collaboration with a team of researchers at the Stanford University School of Medicine led by Michelle James, Ph.D., Assistant Professor of Radiology and Neurology.
Ashvattha Therapeutics announced data from a late-breaking presentation at The Liver Meeting Digital Experience 2020 of the American Association for the Study of Liver Diseases (AASLD), held virtually November 13-16, 2020.
Ashvattha announced the formation of a Scientific Advisory Board. The SAB will work closely with Ashvattha’s management team to select and develop highly differentiated HDTs to treat diseases with significant unmet medical need.
Ashvattha announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.